肿瘤相关性贫血研究进展  

Research progress of cancer related anemia

作　　者：裴王伟 范润萍 徐笑红[1] 陈勇毅 姜慧芬[1] Fan Runping;Xu Xiaohong;Chen Yongyi;Jiang Huifen(Clinical Laboratory,Zhejiang Cancer Hospital,Zhejiang Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院检验科,浙江杭州310022

出　　处：《现代肿瘤医学》2020年第17期3092-3095,共4页Journal of Modern Oncology

摘　　要：肿瘤相关性贫血(cancer related anemia,CRA)是恶性肿瘤的常见并发症。CRA对患者生存、疾病进展、治疗效果和生活质量均有一定的影响。CRA的发病机制复杂且多方面,本文就免疫、营养和代谢成分影响其发病的机制进行讨论。CRA有输血、红系造血刺激剂(erythropoiesis-stimulating agents,ESAs)、补铁等治疗方法。而现有的治疗方法存在一定的局限性,也需要新的安全有效的方法来治疗CRA。Cancer related anemia(CRA)is a common complication of malignant tumors.CRA has a certain impact on survival,disease progression,therapeutic effect and quality of life of patients.The pathogenesis of CRA is complex and multifaceted.The mechanism of immune,nutritional and metabolic components affecting the pathogenesis of CRA is discussed in this paper.The treatment of CRA includes blood transfusion,erythropoiesis-stimulating agents,iron supplementation,etc.However,the existing treatment methods have some limitations,and new safe and effective methods are needed to treat CRA.

关 键 词：肿瘤 贫血 促红细胞生成素 

分 类 号：R730.6[医药卫生—肿瘤]